Metraipolis › archive › dc_3086f45ba712
Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays — Europe PMC PMID:38079206
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38079206
- DOI
- 10.7554/elife.89891
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T11:30:34.952Z
- SHA-256 of the archived text
3155896c0d92b8a906a10de4306c2bf9cce7ad5ba3674f2688791958e8fa1dad- Stable URL of this page
https://metraipolis.com/documento/dc_3086f45ba712
How to cite
Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays — Europe PMC PMID:38079206 — Europe PMC (en), https://europepmc.org/article/MED/38079206 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_3086f45ba712 (Metraipolis archive dc_3086f45ba712, sha256 3155896c0d92b8a906a10de4306c2bf9cce7ad5ba3674f2688791958e8fa1dad)
BibTeX
@misc{dc3086f45ba712,
title = {Allelic strengths of encephalopathy-associated UBA5 variants correlate between in vivo and in vitro assays — Europe PMC PMID:38079206},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38079206},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_3086f45ba712; sha256 3155896c0d92b8a906a10de4306c2bf9cce7ad5ba3674f2688791958e8fa1dad},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38079206. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Protein UFMylation downstream of the E1 enzyme UBA5 plays essential roles in development and endoplasmic reticulum stress. Variants in the UBA5 gene are associated with developmental and epileptic encephalopathy 44 (DEE44), an autosomal recessive disorder characterized by early-onset encephalopathy, movement abnormalities, global developmental delay, intellectual disability, and seizures. DEE44 is caused by at least 12 different missense variants described as loss of function (LoF), but the relationships between genotypes and molecular or clinical phenotypes remain to be established. We developed a humanized UBA5 fly model and biochemical activity assays in order to describe in vivo and in vitro genotype-phenotype relationships across the UBA5 allelic series. In vivo, we observed a broad spectrum of phenotypes in viability, developmental timing, lifespan, locomotor activity, and bang sensitivity. A range of functional effects was also observed in vitro across comprehensive biochemical assays for protein stability, ATP binding, UFM1 activation, and UFM1 transthiolation. Importantly, there is a strong correlation between in vivo and in vitro phenotypes, establishing a classification of LoF variants into mild, intermediate, and severe allelic strengths. By systemically evaluating UBA5 variants across in vivo and in vitro platforms, this study provides a foundation for more basic and translational UBA5 research, as well as a basis for evaluating current and future individuals afflicted with this rare disease. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: eLife, 2023 (prima pubblicazione 2023-12-11). Identificativi: PMID 38079206 · PMCID PMC10712953 · DOI 10.7554/elife.89891. Parole chiave degli autori: Human; Genetics; Genomics; Medicine; D. Melanogaster; Rare Disease; Uba5; Allelic Series; Ufmylation; Developmental And Epileptic Encephalopathy. Descrittori MeSH principali: Brain Diseases; Movement Disorders; Ubiquitin-Activating Enzymes; Intellectual Disability. Pagina: https://europepmc.org/article/MED/38079206 — https://doi.org/10.7554/elife.89891. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T11:17:30.964Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.